AFAlexis Ferré

Alexis Ferré

*This is an algorithmically generated author record based on publicly available information.

Alexis Ferré has a total of 224 co-authors. Here are the top co-authors by number of shared publications:

  • Stéphane Legriel

    Intensive Care Unit, Versailles Hospital, Le Chesnay, France

    5 shared publications
  • Fabrice Bruneel

    4 shared publications
  • Stephane Legriel

    Médecine Intensive Réanimation, Centre Hospitalier de Versailles - Site André Mignot, 177 rue de Versailles, Le Chesnay cedex, 78150, France; IctalGroup, Le Chesnay, France; Université Paris-Saclay, Université de Versailles Saint Quentin enYvelines, Villejuif, 94807, France

    4 shared publications
  • Antoine Gros

    Intensive Care Unit, Versailles Hospital, Le Chesnay, France

    3 shared publications
  • Fabien Marquion

    Department of Anesthesiology, Versailles Hospital, Le Chesnay, France

    3 shared publications
  • Gilles Troché

    Intensive Care Unit, Versailles Hospital, Le Chesnay, France

    3 shared publications

Latest Publications

  • Open Access

    Severe COPD Exacerbators Requiring Multiple ICU Admissions Over Time: Insights of a French Cohort

    by Alexis Ferré, Nassim Sahki, Pauline Puechoultres, Sylvain Diop, Georges Abi-Abdallah, Stéphane Legriel

    Introduction: Data on COPD patients who experience multiple intensive care unit (ICU) admissions for severe acute exacerbations (AECOPD) are scarce. We aimed to describe and compare patients’ characteristics by recurrent admission status and to identify factors associated with recurrent ICU-level exacerbations. Methods: We conducted a single-centre, retrospective cohort study including all patients admitted to our ICU between 2015 and 2022 for a severe AECOPD. Patients with more than one ICU admission during the study period were classified as “recurrent exacerbator” phenotype. Multivariable regression and competing-risk models were used. Results: We included 328 patients who had a total of 445 admissions. Seventy-two (22.0%) patients had multiple ICU admissions. Compared with non-recurrent patients, recurrent exacerbators were younger (median 67 vs 70 years, p=0.037), had a lower prevalence of impaired Performance Status (13.9% vs 25.8%, p=0.035), and had higher blood eosinophil counts (0.06 vs 0.04 G/L, p=0.025). One-year mortality was similar between groups (18.1% vs 18.4%, p=0.95). In multivariate model, factors independently associated with recurrent severe exacerbation were long-term oxygen therapy (HR = 1.79, p=0.045) and initial blood eosinophil count (HR per +0.1 G/L = 1.10, p< 0.001). A Performance Status ≥ 3 was inversely associated with recurrence (HR per point = 0.41, p=0.030). Conclusion: Patients with recurrent ICU admission for severe COPD exacerbations were younger and had higher blood eosinophil counts than those with a single admission. These findings may suggest that phenotyping—including blood eosinophils—could help stratify the risk of recurrent severe exacerbations and personalised treatment.

  • Open Access

    Acute hYpErcapnic respiratory failure in The ICU: A multicenter prospective observational study - The YETI study

    by Claire Dupuis, Toufik Kamel, Christophe Beyls, Charlène Le Moal, Pierre Garcon, Suzanne Goursaud, Laetitia Bodet-Contentin, Alexis Ferré, Max Guillot, Alexandre Gachet, et al.


  • Open Access

    Withholding of Life-Sustaining Treatment and Mortality in ICU Patients with Severe Acute COPD Exacerbations: A Retrospective French Cohort

    by Pauline Puechoultres, Matthieu Jamme, Georges Abi-Abdallah, Sylvain Diop, Stéphane Legriel, Alexis Ferré

    Background: Data on withholding life-support (WLS) decisions during acute exacerbations of chronic obstructive pulmonary disease (COPD) in the intensive care unit (ICU) are scarce. This study aimed to identify factors associated with these decisions and their impact on mortality. Methods: We conducted a monocentric retrospective cohort study on all patients admitted to our ICU between 2015 and 2021 for a severe acute exacerbation of COPD. Logistic multivariable regression analysis was performed. Results: We included 463 patients of whom 128 (27.6%) had a decision of withholding of care. The 3-months mortality was 49.2% and 4.8% in the WLS group and in the no WLS group, respectively. Forty-eight patients (10.4%) had advanced healthcare directives. In multivariable analysis, factors associated with a decision of WLS were higher age (odds ratio [+10 years] = 1.93, p < 0.001), immunodeficiency (OR = 3.07, p < 0.001), higher Performance Status (PS) score (OR [+1 point] = 2.10, p < 0.001), long-term oxygen therapy (OR = 4.11, p < 0.001) and shock after ICU admission (OR = 2.43, p = 0.01). In multivariate analysis, factors significantly associated with 3-month mortality included decision of WLS during ICU (OR = 22.98, p < 0.001) and invasive mechanical ventilation (OR = 2.72, p < 0.001). Conclusion: Approximately 30% of COPD patients underwent a decision to withhold life-sustaining treatment. Higher age, immunosuppression, increased PS score, and long-term oxygen therapy were significantly associated with this decision. Nearly half of the patients died within three months following a withholding of care decision.


  • Open Access

    Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

    by Tanguy Dequidt, Quentin Richier, Céline Louapre, Florence Ader, Yanis Merad, Nicolas Lauwerier, Christine Jacomet, Michel Carles, Charlotte Biron, Vincent Gendrin, et al.


  • Open Access

    Effect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO)

    by Jean-Pierre Frat, Remi Coudroy, Jean-Pierre Quenot, Christophe Guitton, Julio Badie, Arnaud Gacouin, Stephan Ehrmann, Alexandre Demoule, Fabien Jarousseau, Guillaume Carteaux, et al.

    Introduction First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure. Method and analysis The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay. Ethics and dissemination The study has been approved by the central Ethics Committee ‘Sud Méditerranée III’ (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04468126.


  • Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma

    by Stephane Legriel, Rafael Badenes, Nicolas Engrand, Rocio Mendoza-Trujillo, Pauline Soulier, Sarah Benghanem, Michael Pizzi, Carolina Maciel, Jonathan Chelly, Benjamin Zuber, et al.

    Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472


  • Open Access

    Unchanged Characteristics and Survival among Critically Ill COVID-19 Patients during First, Second, and Third Waves: A Prospective Observational Cohort

    by Alexis Ferré, Myriam Lamamri, Marc Delord, Georges Abi-Abdallah, Antoine Gros, Guillaume Lacave, Virginie Laurent, Fabien Marquion, Sybille Merceron, Marine Paul, et al.

    Background: This study was carried out to compare characteristics and outcomes in patients with acute respiratory failure related to COVID-19 during first, second, and third waves. Methods: We included consecutive adults admitted to the intensive care unit between March 2020 and July 2021. We compared three groups defined by the epidemic intake phase: waves 1 (W1), 2 (W2), and 3 (W3). Results: We included 289 patients. Two hundred and eight (72%) patients were men with a median age of 63 years (IQR: 54–72), of whom 68 (23.6%) died in hospital. High-flow nasal oxygen (HFNO) was inversely associated with the need for invasive mechanical ventilation (MV) in multivariate analysis (p = 0.003) but not dexamethasone (p = 0.25). The day-90 mortality rate did not vary from W1 (27.4%) to W2 (23.9%) and W3 (22%), p = 0.67. By multivariate analysis, older age (odds ratio [OR]: 0.94/year, p < 0.001), immunodeficiency (OR: 0.33, p = 0.04), acute kidney injury (OR: 0.26, p < 0.001), and invasive MV (OR: 0.13, p < 0.001) were inversely associated with higher day-90 survival as opposed to the use of intermediate heparin thromboprophylaxis dose (OR: 3.21, p = 0.006). HFNO use and dexamethasone were not associated with higher day-90 survival (p = 0.24 and p = 0.56, respectively). Conclusions: In patients with acute respiratory failure due to COVID-19, survival did not change between first, second, and third waves while the use of invasive MV decreased. HFNO or intravenous steroids were not associated with better outcomes, whereas the use of intermediate dose of heparin for thromboprophylaxis was associated with higher day-90 survival. Larger multicentric studies are needed to confirm our findings.


  • Open Access

    Impact of corticosteroids on the duration of ventilatory support during severe acute exacerbations of chronic obstructive pulmonary disease in patients in the intensive care unit: a study protocol for a multicentre, randomized, placebo-controlled, double-blind trial

    by Alexis Ferré, Arnaud W. Thille, Armand Mekontso-Dessap, Thomas Similowski, Stéphane Legriel, Philippe Aegerter, Alexandre Demoule, The Réseau Européen de Recherche en Ventilation Artificielle (REVA) research network

    Background: Patients who are admitted to the intensive care unit (ICU) for severe acute exacerbations of chronic obstructive pulmonary disease (COPD) have poor outcomes. Although international clinical practice guidelines cautiously recommend the routine use of systemic corticosteroids for COPD exacerbations, data are scarce and inconclusive regarding their benefit for most severe patients who require mechanical ventilation in the ICU. Furthermore, corticosteroids may be associated with an increased risk of infection, ICU-acquired limb weakness, and metabolic disorders. Methods and analysis: This study is an investigator-initiated, multicentre, randomized, placebo-controlled, double-blind trial comparing systemic corticosteroids to placebo during severe acute exacerbations of COPD in patients who require mechanical ventilation in French ICUs. A total of 440 patients will be randomized 1:1 to methylprednisolone (1 mg/kg) or placebo for 5 days, and stratified according to initial mechanical ventilation (non-invasive or invasive), pneumonia as triggering factor, and recent use of systemic corticosteroids (< 48 h). The primary outcome is the number of ventilator-free days at day 28, defined as the number of days alive and without mechanical invasive and/or non-invasive ventilation between randomization and day 28. Secondary outcomes include non-invasive ventilation (NIV) failure rate, duration of mechanical ventilation (invasive and/or NIV), circulatory support (vasopressor), outcomes related to corticosteroid adverse events (severe hyperglycaemia, gastrointestinal bleeding, uncontrolled arterial hypertension, ICU-acquired weakness, ICU-acquired infections, and delirium), lengths of ICU and hospital stay, ICU and hospital mortality, day 28 and day 90 mortality, number of new exacerbation(s)/hospitalization(s) between hospital discharge and day 90, and dyspnoea and comfort at randomization, ICU discharge, and day 90. Subgroup analyses for the primary outcome are planned according to stratification criteria at randomization.


  • Open Access

    Association of ventilator type with hospital mortality in critically ill patients with SARS-CoV2 infection: a prospective study

    by Alexis Ferré, Fabien Marquion, Marc Delord, Antoine Gros, Guillaume Lacave, Virginie Laurent, Sybille Merceron, Marine Paul, Christelle Simon, Gilles Troché, et al.


  • Open Access

    Association of Ventilator Type with Hospital Mortality in Critically Ill Patients with SARS-CoV2 Infection: A Retrospective Study.

    by Alexis Ferre, Fabien Marquion, Marc Delord, Jean-Pierre Bédos, Hugo Bellut, Antoine Gros, Juliana Henao-Brasseur, Guillaume Lacave, Virginie Laurent, Marine Paul, et al.

    Background: To evaluate the association between ventilator type and hospital mortality in patients with acute respiratory distress syndrome (ARDS) related to COVID-19 (SARS-CoV2 infection) during the first wave of the disease in France.Methods: We retrospectively included consecutive adults admitted to the intensive care unit (ICU) of a university-affiliated tertiary hospital for ARDS related to proven COVID-19, between March and May 2020. All patients were intubated. We compared two patient groups defined by whether an ICU ventilator or a less sophisticated ventilator such as a transport ventilator was used. Kaplan-Meier survival curves were plotted. Cox multivariate regression was performed to identify associations between patient characteristics and hospital mortality.Results: We included 82 patients (61 [74.4%] men) with a median age of 64 years [55–74], of whom 23 (28.1%) died before hospital discharge. By multivariate analysis, factors associated with in-hospital mortality were older age (HR, 1.06/year; 95%CI, 1.00–1.11; P=0.05) and diabetes mellitus (HR, 3.32; 95%CI, 1.13–9.76; P=0.03) but not ventilator type. Using non-ICU ventilator was associated neither with a longer duration of invasive mechanical ventilation (20 [12-36] vs. 25 [15-31] days; P=0.87) nor with a longer ICU stay (24 [14-40] vs. 27 [15-37] days; P=0.64).Conclusions: In patients with ARDS due to COVID-19, the use of non-ICU ventilators, such as transport ventilators, was not associated with worse outcomes. Although prospective data are needed to confirm our findings, this study suggests that transport ventilators may be valuable during COVID-19 surges that overwhelm ICU resources.